Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Maziarz

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Current Opinion in Hematology|February 28, 2008
Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?Richard T Maziarz
Best Practice & Research. Clinical Haematology|April 24, 2025
The history of cytokines and growth factors developmentSmith Kungwankiattichai, Richard T Maziarz
Med (New York, N.Y.)|May 19, 2022
The evolving need for patient reported outcome data in determining choice of immune therapy treatmentJennifer Saultz, Richard T Maziarz
Archives of Stem Cell and Therapy|January 3, 2023
Post-allogeneic stem cell transplant <i>FLT3</i>- targeted maintenance therapy: updates and considerations for clinical practiceJonathan Cohen, Richard T Maziarz
Expert Opinion on Drug Discovery|October 3, 2025
The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphomaSmith Kungwankiattichai, Richard T Maziarz
Current Oncology Reports|August 12, 2006
Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantationTibor Kovacsovics, Richard T Maziarz
Cell Stem Cell|June 1, 2011
Hematopoietic stem cell transplantation and implications for cell therapy reimbursementRichard T Maziarz, Dawn Driscoll
Mayo Clinic Proceedings|March 15, 2006
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?Michael J Mauro, Richard T Maziarz
Current Opinion in Hematology|January 15, 2013
Hematopoietic stem cell transplantation for myelofibrosis: where are we now?Angela G Fleischman, Richard T Maziarz
Hematology (Amsterdam, Netherlands)|May 7, 2024
The rationale behind grafting haploidentical hematopoietic stem cellsRichard T Maziarz, Rachel J Cook
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Current Opinion in Hematology|February 28, 2008
Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?Richard T Maziarz
Best Practice & Research. Clinical Haematology|April 24, 2025
The history of cytokines and growth factors developmentSmith Kungwankiattichai, Richard T Maziarz
Med (New York, N.Y.)|May 19, 2022
The evolving need for patient reported outcome data in determining choice of immune therapy treatmentJennifer Saultz, Richard T Maziarz
Archives of Stem Cell and Therapy|January 3, 2023
Post-allogeneic stem cell transplant <i>FLT3</i>- targeted maintenance therapy: updates and considerations for clinical practiceJonathan Cohen, Richard T Maziarz
Expert Opinion on Drug Discovery|October 3, 2025
The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphomaSmith Kungwankiattichai, Richard T Maziarz
Current Oncology Reports|August 12, 2006
Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantationTibor Kovacsovics, Richard T Maziarz
Cell Stem Cell|June 1, 2011
Hematopoietic stem cell transplantation and implications for cell therapy reimbursementRichard T Maziarz, Dawn Driscoll
Mayo Clinic Proceedings|March 15, 2006
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?Michael J Mauro, Richard T Maziarz
Current Opinion in Hematology|January 15, 2013
Hematopoietic stem cell transplantation for myelofibrosis: where are we now?Angela G Fleischman, Richard T Maziarz
Hematology (Amsterdam, Netherlands)|May 7, 2024
The rationale behind grafting haploidentical hematopoietic stem cellsRichard T Maziarz, Rachel J Cook
Pageof 24